Press Releases

GlobeNewswire, Inc.

CLYM116 Phase 1 data in healthy volunteers showed sustained >90% free APRIL suppression and ~70% Gd-IgA1 reduction at 12 weeks after a single dose, supporting every-12-week dosing Initiated dosing in NAVIGATE-2 Phase 2 trial of CLYM116 in IgAN;...

GlobeNewswire, Inc.

Q3 2026 EPS Exceeded the Guidance, Both Revenue and GM In-Line With Guidance Issued on Aug. 6, 2026 Company Q4 2026 Guidance: Revenues to Decrease 22% to 26%, Gross Margin is Expected to be Flat to Slightly up. Profit per Diluted ADS to be 4.5...

GlobeNewswire, Inc.

Worldwide revenue of $389.9 million in the third quarter of 2026 GAAP fully diluted earnings per share of $0.33, compared to $0.41 in the third quarter of 2025 Adjusted fully diluted earnings per share of $1.68, compared to $1.27 in the third...

EIN Presswire

DALLAS, TX, UNITED STATES, November 5, 2026 /⁨EINPresswire.com⁩/ -- The National Financial Educators Council (NFEC) is launching its Caribbean chapter to support financial educators, strengthen local programmes, and connect organisations committed...

GlobeNewswire, Inc.

Completed Statistical Analyses of LEVEL Yielded a Predictive Enrichment Strategy Being Applied in Amended LEVEL-2 Protocol Company Has Been Granted a Type C Meeting with the FDA CHAPEL HILL, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tenax...

GlobeNewswire, Inc.

- Initiation of Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus Expected in Fourth Quarter of 2026 - - Timeline Reaffirmed for Top Line Results from Phase 2 ADMIRATION Trial of Bosakitug (ATI-045) in Atopic Dermatitis (AD) - - Positive...

GlobeNewswire, Inc.

Reported total revenue of $14.0 million in the third quarter of 2026 driven by 17% growth in the Surgical Aesthetics segment Initiated successful full commercial launch of the power liposuction handpiece for the AYON system in the third quarter...

GlobeNewswire, Inc.

Phase 3 SONATA-HCM study substantially overenrolled; top-line data expected Q1 2027 Positive STENO1 safety data strengthens benefit-risk profile for ZYNQUISTA® NDA resubmission Phase 1 clinical development of LX9851 ongoing by Novo Conference call...

GlobeNewswire, Inc.

Safety profile presented at ASN Kidney Week 2026 across 29 autoimmune patients treated with a single dose of FT819 and fludarabine-free, less-intensive conditioning continues to be favorable, further supporting RECLAIM-LN Preliminary Phase 1...

GlobeNewswire, Inc.

Started dosing healthy volunteers with KRRO-121 in the Phase 1/2 clinical trial (ANCHOR) Expect to dose participants with Urea Cycle Disorders (UCDs) in the first half of 2027 Anticipate reporting interim data in the second half of 2027 Achieved...

GlobeNewswire, Inc.

-- All ELEVATE-44-201 Cohort 1 participants have completed open-label dosing, with data expected to be received by year-end 2026 -- -- Company on track to report ELEVATE-44-201 Cohort 2 data in Q1 2027 – -- ELEVATE-45-201 Cohort 1 data reported in...

GlobeNewswire, Inc.

Phase 3 bunionectomy and open-label safety trials of onzotrigine remain on track for initiation with topline results expected in the second half of 2027 Company plans to add oxycodone/acetaminophen (commonly known as Percocet) as opioid comparator...

GlobeNewswire, Inc.

Revenue of $673.8 million and Direct-to-Consumer (“DTC”) Revenue of $275.1 million Revenue Decreased (7.8)% Sequentially and (0.1)% Year Over Year DTC Platforms Revenue Decreased (4.1)% Sequentially and Increased 31.4% Year Over Year HERZLIYA,...

GlobeNewswire, Inc.

New National University (NU) students can file the Free Application for Federal Student Aid (FAFSA) and complete requested documents before their first course starts, so packaging can begin early Under typical processing conditions, NU generally...

GlobeNewswire, Inc.

Revising 2026 outlook higher and extending to a five-year outlook through to 2031 Announced approximately $3 billion of new growth projects CALGARY, Alberta, Nov. 05, 2026 (GLOBE NEWSWIRE) -- TC Energy Corporation (TSX, NYSE: TRP) (TC Energy or...

GlobeNewswire, Inc.

Q3 2026 revenue of $85 million, up 71% quarter-over-quarter and above the high end of outlook Q3 2026 net loss of $10 million; Adjusted EBITDA of $20 million, above the high end of outlook Received initial Energy Industrial data center...

GlobeNewswire, Inc.

Mitapivat (PYRUKYND® and AQVESME®) delivered worldwide net revenues of $55.4 million in third quarter of 2026, more than four times the $12.9 million reported in third quarter of 2025 Strong U.S. demand for AQVESME in thalassemia continues, with...

GlobeNewswire, Inc.

Results for the Quarter Ended September 30, 2026, and Other Recent Highlights: Net investment income per share for the quarter was $0.34, compared to $0.40 for the quarter ended June 30, 2026 Net asset value (“NAV”) per share as of the end of the...

GlobeNewswire, Inc.

HOUSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Targa Resources Corp. (NYSE: TRGP) (“TRGP,” the “Company” or “Targa”) today reported third quarter 2026 results.

GlobeNewswire, Inc.

The Board approved plan targets a 25%–30% reduction in annualized operating expenses, compared to annualized 2026 GAAP and non-GAAP operating expenses, once fully implemented, expected by the end of Q1 2027 Cost reduction aims to advance four...